139 related articles for article (PubMed ID: 12000825)
41. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole.
Antachopoulos C; Papakonstantinou E; Dotis J; Bibashi E; Tamiolaki M; Koliouskas D; Roilides E
J Pediatr Hematol Oncol; 2005 May; 27(5):283-5. PubMed ID: 15891566
[TBL] [Abstract][Full Text] [Related]
42. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
Santos RP; Sánchez PJ; Mejias A; Benjamin DK; Walsh TJ; Patel S; Jafri HS
Pediatr Infect Dis J; 2007 Apr; 26(4):364-6. PubMed ID: 17414408
[TBL] [Abstract][Full Text] [Related]
43. [Meta-analysis on safety and efficacy of liposomal amphotericin B in the empirical treatment of febrile neutropenia].
Badia X; Roset M; Carreras E; Ausin I; Herrera L
Med Clin (Barc); 2004 May; 122(16):610-6. PubMed ID: 15142508
[TBL] [Abstract][Full Text] [Related]
44. Caspofungin: new indication. No progress in invasive candidiasis.
Prescrire Int; 2004 Apr; 13(70):48-9. PubMed ID: 15148956
[TBL] [Abstract][Full Text] [Related]
45. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.
Wingard JR; White MH; Anaissie E; Raffalli J; Goodman J; Arrieta A;
Clin Infect Dis; 2000 Nov; 31(5):1155-63. PubMed ID: 11073745
[TBL] [Abstract][Full Text] [Related]
46. A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment.
Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Mahi L; Deray G
Nephrol Dial Transplant; 2007 Oct; 22(10):3090-1. PubMed ID: 17595189
[No Abstract] [Full Text] [Related]
47. [New development in the treatment of deep-seated mycoses].
Maesaki S
Nihon Naika Gakkai Zasshi; 2007 Sep; 96(9):1993-8. PubMed ID: 17929445
[No Abstract] [Full Text] [Related]
48. Caspofungin versus liposomal amphotericin B for empirical therapy.
Marty FM; Lowry CM
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675093
[No Abstract] [Full Text] [Related]
49. Liposomal amphotericin B for fever and neutropenia.
Wingard JR
N Engl J Med; 1999 Oct; 341(15):1153; author reply 1154-5. PubMed ID: 10515753
[No Abstract] [Full Text] [Related]
50. Amphotericin B is still the drug of choice for invasive aspergillosis.
Agarwal R; Singh N
Am J Respir Crit Care Med; 2006 Jul; 174(1):102; author reply 102-3. PubMed ID: 16793999
[No Abstract] [Full Text] [Related]
51. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A
J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146
[TBL] [Abstract][Full Text] [Related]
52. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.
Fournier S; Pavageau W; Feuillhade M; Deplus S; Zagdanski AM; Verola O; Dombret H; Molina JM
Eur J Clin Microbiol Infect Dis; 2002 Dec; 21(12):892-6. PubMed ID: 12525928
[TBL] [Abstract][Full Text] [Related]
53. Successful use of combination antifungal therapy in the treatment of coccidioides meningitis.
Antony SJ; Jurczyk P; Brumble L
J Natl Med Assoc; 2006 Jun; 98(6):940-2. PubMed ID: 16775917
[TBL] [Abstract][Full Text] [Related]
54. Breakthrough disseminated fusariosis in an immunocompromised patient on voriconazole therapy.
Kim MS; Lee HM; Sung HS; Won CH; Chang SE; Lee MW; Choi JH; Moon KC
Int J Dermatol; 2012 May; 51(5):621-3. PubMed ID: 21790547
[No Abstract] [Full Text] [Related]
55. Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis.
Cudillo L; Girmenia C; Santilli S; Picardi A; Dentamaro T; Tendas A; de Fabritiis P
Clin Infect Dis; 2005 Apr; 40(8):1212-3. PubMed ID: 15791530
[No Abstract] [Full Text] [Related]
56. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia.
Frothingham R
Clin Infect Dis; 2002 Oct; 35(7):896-7; author reply 897-8. PubMed ID: 12228830
[No Abstract] [Full Text] [Related]
57. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients.
Bennett JE; Powers J; Walsh T; Viscoli C; de Pauw B; Dismukes W; Galgiani J; Glauser M; Herbrecht R; Kauffman C; Lee J; Pappas P; Rex J; Verweij P
Clin Infect Dis; 2003 Apr; 36(Suppl 3):S117-22. PubMed ID: 12679895
[TBL] [Abstract][Full Text] [Related]
58. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model.
Takemoto K; Yamamoto Y; Ueda Y; Kanazawa K; Yoshida K; Niki Y
Chemotherapy; 2009; 55(2):105-13. PubMed ID: 19151551
[TBL] [Abstract][Full Text] [Related]
59. Invasive cutaneous infection with Geotrichum candidum: sequential treatment with amphotericin B and voriconazole.
Sfakianakis A; Krasagakis K; Stefanidou M; Maraki S; Koutsopoulos A; Kofteridis D; Samonis G; Tosca A
Med Mycol; 2007 Feb; 45(1):81-4. PubMed ID: 17325948
[TBL] [Abstract][Full Text] [Related]
60. Liposomal amphotericin B for fever and neutropenia.
Fischer T; Heussel G; Huber C
N Engl J Med; 1999 Oct; 341(15):1152; author reply 1154-5. PubMed ID: 10515750
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
